Clinical Trials Browser

Phase 1/2 × Has results × exemestane × Clear all

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

NCT02871791 2022-08-29

Palbociclib With Everolimus + Exemestane In BC

Phase 1/2 Completed

41 enrolled 12 charts

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

NCT02732119 2021-05-05

TRINITI-1

Phase 1/2 Completed

104 enrolled 24 charts

Breast Neoplasms

NCT00905021 2020-07-24

EXTENT

Phase 1/2 Terminated

4 enrolled 6 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02983604 2019-08-07

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Phase 1/2 Terminated

14 enrolled 13 charts

Breast Neoplasms

NCT01484041 2018-02-09

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Phase 1/2 Terminated

12 enrolled 7 charts

Breast Neoplasms

NCT01202591 2016-02-11

GLOW

Phase 1/2 Completed

127 enrolled 8 charts

Breast Neoplasms

NCT00417885 2010-09-21

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Phase 1/2 Terminated

6 enrolled 6 charts

Breast Neoplasms